IOVA vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IOVA presents a classic high-risk, high-reward biotechnology profile, characterized by a stable Piotroski F-Score of 4/9 and a lack of traditional valuation metrics like the Graham Number due to negative earnings. While the company maintains a strong liquidity position with a current ratio of 3.20 and very low debt (D/E 0.07), it suffers from severe profitability issues with a profit margin of -148.38%. The stark contrast between the bearish technical trend (0/100) and the aggressive analyst target price of $9.00 suggests a speculative environment where fundamental health is secondary to future growth expectations.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
IOVA vs LLY: Head-to-Head Comparison
This page compares Iovance Biotherapeutics, Inc. (IOVA) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.